ArticleESMO open2026

Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial.

Y Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.